Case reportPeripartum cardiomyopathy—a new treatment option by inhibition of prolactin secretion
Section snippets
Case Report
A 43-year-old primigravida with uneventful history and family history was transferred at 34 +2 weeks of gestation due to preeclampsia and suspected hemolysis, elevated liver enzyme levels, low platelet count (HELLP) syndrome. The patient showed slightly elevated blood pressure (145/95 mmHg) and proteinuria (protein 100 mg/dL). Ultrasonography showed apart from oligohydramnion (amnion fluid index 4) a fetal weight estimation and Doppler measuments of fetal and maternal vessels within normal
Comment
A 16 kDa prolactin derivate promotes endothelial cell apoptosis, disrupts capillary structures, and impairs cardiomyocyte metabolism and contractility.7, 8, 9 Recent experimental data implicate a causal role of the cleaved 16 kDa prolactin for the development of PPCM in mice with a cardiac restricted deletion of the signal transducer and activator of transcription-3 (STAT-3).7
Suppression of prolactin secretion with Bromocriptine averts PPCM in these mice. Most importantly, Bromocriptine
References (10)
- et al.
Peripartum cardiomyopathy
Lancet
(2006) - et al.
Incidence, mortality, and racial differences in peripartum cardiomyopathy
Am J Cardiol
(2007) - et al.
Improved outcomes in peripartum cardiomyopathy with contemporary
Am Heart J
(2006) - et al.
Peripartum cardiomyopathy: Analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1
J Am Coll Cardiol
(2000) - et al.
A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy
Cell
(2007)
Cited by (51)
Managing Specific Cardiac Conditions During Pregnancy, Labor, and Delivery
2022, Maternal Cardiac Care: A Guide to Managing Pregnant Women with Heart DiseasePregnancy and Heart Disease: Pregnancy-Associated Hypertension and Peripartum Cardiomyopathy
2018, Current Problems in CardiologyPeripartum cardiomyopathy
2018, Archives des Maladies du Coeur et des Vaisseaux - PratiqueProlactin
2015, Endocrinology: Adult and PediatricThe Medical Treatment of New-Onset Peripartum Cardiomyopathy: A Systematic Review of Prospective Studies
2015, Canadian Journal of CardiologyCitation Excerpt :In addition, cardiac valve fibrosis and regurgitation have been reported with the long-term use of dopamine agonists for Parkinson disease.34,35 The promise of bromocriptine as a therapeutic option in adults with acute PPCM was first reported in a case report of 2 patients in 2007.36,37 After these results, an open-label randomized trial published in 2010 was conducted to investigate bromocriptine (2.5 mg orally twice daily for 2 weeks, followed by bromocriptine 2.5 mg orally once daily for 6 weeks) added to usual medical care compared with usual medical care alone in 20 South African patients with PPCM.18
Sex differences in cardivascular diseases
2022, Krankenhauspharmazie